{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:53:31Z","timestamp":1794725611812,"version":"4.9.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.drugalcdep.2020.108336","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T01:43:07Z","timestamp":1601689387000},"page":"108336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study"],"prefix":"10.1016","volume":"217","author":[{"given":"Arnie P.","family":"Aldridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Barocas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagpreet","family":"Chhatwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J.","family":"Harlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaz","family":"Hyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"McCollister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake R.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Savitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Schackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E.","family":"Seiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"E Starbird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Zarkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2020.108336_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2020.03.015","article-title":"Economic evaluation of interventions to address opioid misuse: a systematic review of methods used in simulation modeling studies","author":"Barbosa","year":"2020","journal-title":"Value in Health"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.drugpo.2019.05.010","article-title":"Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV\/hepatitis C co-infection who inject opioids","volume":"72","author":"Barocas","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/ADM.0000000000000488","article-title":"Hospital-based addiction medicine healthcare providers: high demand, short supply","volume":"13","author":"Braithwaite","year":"2019","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hec.766","article-title":"Missing\u2026 presumed at random: cost-analysis of incomplete data","volume":"12","author":"Briggs","year":"2003","journal-title":"Health Econ."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0025","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0030","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/add.13900","article-title":"Cost-effectiveness of emergency department-initiated treatment for opioid dependence","volume":"112","author":"Busch","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W","article-title":"Modelling in economic evaluation: an unavoidable fact of life","volume":"6","author":"Buxton","year":"1997","journal-title":"Health Econ."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7621","article-title":"Prevention of prescription opioid misuse and projected overdose deaths in the United States","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0045","first-page":"3","article-title":"Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs","author":"Chhatwal","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-158-1-201301010-00003","article-title":"Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal","volume":"158","author":"Coffin","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0055","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0060","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2018.07.014","article-title":"Re-engineering methadone-cost-effectiveness analysis of a patient-centered approach to methadone treatment","volume":"94","author":"Dunlap","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0065","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1176\/appi.ps.201800445","article-title":"Screening and intervention for suicide prevention: a cost-effectiveness analysis of the ED-SAFE interventions","volume":"70","author":"Dunlap","year":"2019","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0070","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"32","author":"Eddy","year":"2012","journal-title":"Med. Decis. Making"},{"issue":"12","key":"10.1016\/j.drugalcdep.2020.108336_bib0075","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials","volume":"32","author":"Faria","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.engstruct.2017.11.005","article-title":"Metamodel-based design optimization of structural one-way slabs based on deep learning neural networks to reduce environmental impact","volume":"155","author":"Ferreiro-Cabello","year":"2018","journal-title":"Eng. Struct."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0085","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","article-title":"The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013","volume":"54","author":"Florence","year":"2016","journal-title":"Med. Care"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0090","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/add.13073","article-title":"A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence","volume":"110","author":"Gisev","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0095","series-title":"Economic Evaluation in Clinical Trials","author":"Glick","year":"2014"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108042","article-title":"Cost-effectiveness analysis of a large jail-based methadone maintenance treatment continuation program in New Mexico","author":"Horn","year":"2020","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0105","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/pme.12183","article-title":"The economic burden of opioid-related poisoning in the United States","volume":"14","author":"Inocencio","year":"2013","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0110","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0115","doi-asserted-by":"crossref","first-page":"108330","DOI":"10.1016\/j.drugalcdep.2020.108330","article-title":"Model and approach for assessing implementation context and fidelity in the HEALing Communities Study","volume":"217","author":"Knudsen","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M17-0611","article-title":"Cost-effectiveness of publicly funded treatment of opioid use disorder in California","volume":"168","author":"Krebs","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11121-011-0259-9","article-title":"Cost-benefit analysis of communities that care outcomes at eighth grade","volume":"13","author":"Kuklinski","year":"2012","journal-title":"Prev. Sci."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11292-014-9226-3","article-title":"Benefit\u2013cost analysis of a randomized evaluation of communities that care: monetizing intervention effects on the initiation of delinquency and substance use through grade 12","volume":"11","author":"Kuklinski","year":"2015","journal-title":"J. Exp. Criminol."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0135","doi-asserted-by":"crossref","first-page":"108338","DOI":"10.1016\/j.drugalcdep.2020.108338","article-title":"Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing Communities Study","volume":"217","author":"Lefebvre","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0140","first-page":"S243","article-title":"The economic burden of the opioid epidemic on states: the case of medicaid","volume":"25","author":"Leslie","year":"2019","journal-title":"Am. J. Manage. Care"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jsat.2017.07.008","article-title":"Monetary conversion factors for economic evaluations of substance use disorders","volume":"81","author":"McCollister","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drugpo.2019.06.019","article-title":"They\u2019re making it so hard for people to get help:\" motivations for non-prescribed buprenorphine use in a time of treatment expansion","volume":"71","author":"McLean","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0155","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.2908","article-title":"Assessment of opioid prescribing practices before and after implementation of a health system intervention to reduce opioid overprescribing","volume":"1","author":"Meisenberg","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0165","first-page":"1","article-title":"Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials","author":"Michalowsky","year":"2020","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0170","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40273-016-0400-5","article-title":"Economic evaluations of opioid use disorder interventions","volume":"34","author":"Murphy","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0175","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/add.13807","article-title":"Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder","volume":"112","author":"Murphy","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0180","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse","volume":"170","author":"Murphy","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0185","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2017\u20132018","volume":"vol. 69","author":"Nana","year":"2020"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0190","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2018.6072","article-title":"QALYs in 2018-advantages and concerns","volume":"319","author":"Neumann","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0195","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0200","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2016"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0205","article-title":"How simulation modeling can support the public health response to the opioid crisis in North America: setting priorities and assessing value","author":"Nosyk","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2105\/AJPH.2018.304320","article-title":"Long-term effects of the communities that care trial on substance use, antisocial behavior, and violence through age 21 years","volume":"108","author":"Oesterle","year":"2018","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0215","article-title":"The opioid epidemic and Medicaid\u2019s role in facilitating access to treatment","author":"Orgera","year":"2019","journal-title":"Henry J. Kaiser Family Foundation"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0220","doi-asserted-by":"crossref","first-page":"18","DOI":"10.18553\/jmcp.2019.25.1.018","article-title":"The prevalence and cost of medicare beneficiaries diagnosed and at risk for opioid abuse, dependence, and poisoning","volume":"25","author":"Roland","year":"2019","journal-title":"J. Manage. Care Spec. Pharm."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0225","series-title":"Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, HHS Publication No. PEP19-5068, NSDUH Series H-54; Rockville, MD","article-title":"Key substance use and mental health indicators in the United States: results from the 2018 national survey on drug use and health","author":"SAMHSA","year":"2019"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0230","first-page":"1","article-title":"Exploring the economic effects of the opioid epidemic","volume":"4","author":"Scavette","year":"2019","journal-title":"Econ. Insights"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0235","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MLR.0000000000001107","article-title":"Revenue losses to state and federal government from opioid-related employment reductions","volume":"57","author":"Segel","year":"2019","journal-title":"Med. Care"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0240","doi-asserted-by":"crossref","first-page":"108328","DOI":"10.1016\/j.drugalcdep.2020.108328","article-title":"Operationalizing and selecting outcome measures for the HEALing Communities Study","volume":"217","author":"Slavova","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0245","doi-asserted-by":"crossref","first-page":"108326","DOI":"10.1016\/j.drugalcdep.2020.108326","article-title":"Community engagement to implement evidence-based practices in the HEALing Communities Study","volume":"217","author":"Sprague Martinez","year":"2020","journal-title":"Drug Alcohol Depend ."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0250","article-title":"HEALing (Helping to End Addiction Long-term) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an Integrated set of evidence-based practices","volume":"217","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.07.031","article-title":"Cost-effectiveness analysis of alternative naloxone distribution strategies: first responder and lay distribution in the United States","volume":"75","author":"Townsend","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0260","doi-asserted-by":"crossref","first-page":"108325","DOI":"10.1016\/j.drugalcdep.2020.108325","article-title":"The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study","volume":"217","author":"Winhusen","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0265","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","article-title":"Treatment utilization among persons with opioid use disorder in the United States","volume":"169","author":"Wu","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108336_bib0270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.evalprogplan.2003.09.002","article-title":"The substance abuse services cost analysis program (SASCAP): a new method for estimating drug treatment services costs","volume":"27","author":"Zarkin","year":"2004","journal-title":"Eval. Program Plann."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620305019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620305019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:12:07Z","timestamp":1759828327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871620305019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":54,"alternative-id":["S0376871620305019"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108336","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108336"}}